Literature DB >> 29467073

The Consumption of New Psychoactive Substances and Methamphetamine.

Elena Gomes de Matos1, Tessa-Virginia Hannemann, Josefine Atzendorf, Ludwig Kraus, Daniela Piontek.   

Abstract

BACKGROUND: The abuse of new psychoactive substances (NPS) and methamphetamine has severe adverse effects. Here we provide the first report of regional patterns in NPS and methamphetamine consumption in Germany, on the basis of epidemiologic data from six federal states (Bavaria, Hamburg, Hesse, North Rhine-Westphalia, Saxony, and Thuringia).
METHODS: Data were derived from the 2015 Epidemiological Survey of Substance Abuse (Epidemiologischer Suchtsurvey) and supplemented with additional cases from the federal states that were studied. The numbers of persons included in the representative samples of persons aged 18 to 64 in each state were 1916 (Bavaria), 1125 (Hamburg), 1151 (Hesse), 2008 (North Rhine-Westphalia), 1897 (Saxony), and 1543 (Thuringia). Potential risk factors for the lifetime prevalence of consumption were studied by logistic regression.
RESULTS: The lifetime prevalence of methamphetamine consumption in the individual states ranged from 0.3% (North Rhine-Westphalia) to 2.0% (Saxony). Thuringia and Saxony displayed values that were significantly higher than average. For NPS, the figures ranged from 2.2% (Bavaria) to 3.9% (Hamburg), but multivariate analysis revealed no statistically significant differences between the states. Higher age and higher educational level were associated with lower consumption of NPS and methamphetamine, while smoking and cannabis use were each associated with higher consumption.
CONCLUSION: NPS consumption is equally widespread in all of the federal states studied. Methamphetamine is rarely consumed; its consumption appears to be higher in Saxony and Thuringia. The risk factor analysis reported here should be interpreted cautiously in view of the low case numbers with respect to consumption.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467073      PMCID: PMC5801482          DOI: 10.3238/arztebl.2018.0049

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  18 in total

Review 1.  Major physical and psychological harms of methamphetamine use.

Authors:  Shane Darke; Sharlene Kaye; Rebecca McKetin; Johan Duflou
Journal:  Drug Alcohol Rev       Date:  2008-05

2.  Methamphetamine-Related Disorders.

Authors:  Euphrosyne Gouzoulis-Mayfrank; Roland Härtel-Petri; Willem Hamdorf; Ursula Havemann-Reinecke; Stephan Mühlig; Norbert Wodarz
Journal:  Dtsch Arztebl Int       Date:  2017-06-30       Impact factor: 5.594

Review 3.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

4.  Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products.

Authors:  Luca Zamengo; Giampietro Frison; Chiara Bettin; Rocco Sciarrone
Journal:  Toxicol Lett       Date:  2014-06-06       Impact factor: 4.372

5.  Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.

Authors:  Joseph J Palamar; Silvia S Martins; Mark K Su; Danielle C Ompad
Journal:  Drug Alcohol Depend       Date:  2015-09-03       Impact factor: 4.492

Review 6.  A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.

Authors:  Robert J Tait; David Caldicott; David Mountain; Simon L Hill; Simon Lenton
Journal:  Clin Toxicol (Phila)       Date:  2015-11-15       Impact factor: 4.467

7.  Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.

Authors:  Milana Zaurova; Robert S Hoffman; David Vlahov; Alex F Manini
Journal:  J Med Toxicol       Date:  2016-06-02

Review 8.  Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.

Authors:  Nicolas Hohmann; Gerd Mikus; David Czock
Journal:  Dtsch Arztebl Int       Date:  2014-02-28       Impact factor: 5.594

9.  Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

Authors:  Ulrich S Zimmermann; Patricia R Winkelmann; Max Pilhatsch; Josef A Nees; Rainer Spanagel; Katja Schulz
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

Review 10.  The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis.

Authors:  Seena Fazel; Vivek Khosla; Helen Doll; John Geddes
Journal:  PLoS Med       Date:  2008-12-02       Impact factor: 11.069

View more
  4 in total

1.  The Use of Alcohol, Tobacco, Illegal Drugs and Medicines: An Estimate of Consumption and Substance-Related Disorders in Germany.

Authors:  Josefine Atzendorf; Christian Rauschert; Nicki-Nils Seitz; Kirsten Lochbühler; Ludwig Kraus
Journal:  Dtsch Arztebl Int       Date:  2019-09-02       Impact factor: 5.594

2.  Pattern of novel psychoactive substance use among patients presented to the poison control centre of Ain Shams University Hospitals, Egypt: A cross-sectional study.

Authors:  Ahmed Hashim; Nouran A Mohammed; AlFadl Othman; Mohab A K Gab-Allah; Ahmed H M Al-Kahodary; Eslam R Gaber; Ahmed M Hassan; Mahmoud Aranda; Rania Hussien; Amany Mokhtar; Md Saiful Islam; Ka Yiu Lee; Muhammad Sohaib Asghar; Muhammad Junaid Tahir; Zohaib Yousaf
Journal:  Heliyon       Date:  2022-08-12

3.  Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.

Authors:  Michael Specka; Thomas Kuhlmann; Jürgen Sawazki; Udo Bonnet; Renate Steinert; Monika Cybulska-Rycicki; Helmut Eich; Benita Zeiske; Antje Niedersteberg; Luzia Schaaf; Norbert Scherbaum
Journal:  Front Psychiatry       Date:  2020-07-07       Impact factor: 4.157

Review 4.  Methamphetamine-related cardiovascular diseases.

Authors:  Valentin Schwarzbach; Karsten Lenk; Ulrich Laufs
Journal:  ESC Heart Fail       Date:  2020-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.